title: A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents.
abstract: Isoprenoid biosynthesis is essential for survival of all living organisms. More than 50,000 unique isoprenoids occur naturally, with each constructed from two simple five-carbon precursors: isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). Two pathways for the biosynthesis of IPP and DMAPP are found in nature. Humans exclusively use the mevalonate (MVA) pathway, while most bacteria, including all Gram-negative and many Gram-positive species, use the unrelated methylerythritol phosphate (MEP) pathway. Here we report the development of a novel, whole-cell phenotypic screening platform to identify compounds that selectively inhibit the MEP pathway. Strains of Salmonella enterica serovar Typhimurium were engineered to have separately inducible MEP (native) and MVA (nonnative) pathways. These strains, RMC26 and CT31-7d, were then used to differentiate MVA pathway- and MEP pathway-specific perturbation. Compounds that inhibit MEP pathway-dependent bacterial growth but leave MVA-dependent growth unaffected represent MEP pathway-selective antibacterials. This screening platform offers three significant results. First, the compound is antibacterial and is therefore cell permeant, enabling access to the intracellular target. Second, the compound inhibits one or more MEP pathway enzymes. Third, the MVA pathway is unaffected, suggesting selectivity for targeting the bacterial versus host pathway. The cell lines also display increased sensitivity to two reported MEP pathway-specific inhibitors, further biasing the platform toward inhibitors selective for the MEP pathway. We demonstrate development of a robust, high-throughput screening platform that combines phenotypic and target-based screening that can identify MEP pathway-selective antibacterials simply by monitoring optical density as the readout for cell growth/inhibition.
authors: Echelon Biosciences, Inc., Salt Lake City, Utah, USA. ctesta@echelon-inc.com
authors: Charles A
authors: CA
authors: Testa
authors: L Jeffrey
authors: LJ
authors: Johnson
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D053898:Biosynthetic Pathways / Q000187:drug effects*; D002463:Cell Membrane Permeability; D005578:Fosfomycin / Q000494:pharmacology; D045782:Hemiterpenes / Q000378:metabolism*; D057166:High-Throughput Screening Assays; D060847:Metabolic Engineering; D008826:Microbial Sensitivity Tests; D009943:Organophosphorus Compounds / Q000378:metabolism*; D012486:Salmonella typhimurium / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism*; D013729:Terpenes / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D045782:Hemiterpenes; D009943:Organophosphorus Compounds; D013729:Terpenes; D005578:Fosfomycin; C004809:isopentenyl pyrophosphate; C043060:3,3-dimethylallyl pyrophosphate